Testing immunotherapy for ctDNA-positive colorectal cancer after treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your colorectal cancer and at least 3 months of chemotherapy afterward.
- A blood test after your treatment shows tiny bits of cancer DNA (ctDNA) still present.
- Your tumor type is MSS (microsatellite stable) or pMMR (proficient mismatch repair).
- You are in generally good health (able to do daily activities) and your blood counts, liver, and kidney function are within safe limits.
- You have not had immunotherapy or other cancer treatments in the last 4 weeks, and you don't have an active autoimmune disease or serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests whether giving more chemotherapy can help people who still have cancer DNA in their blood after surgery and standard chemotherapy for colorectal cancer. The goal is to prevent the cancer from coming back.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests two immunotherapy drugs given before surgery for colon cancer that has not spread. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.